About CND Life Sciences
CND Life Sciences is a company based in Phoenix (United States) founded in 2017 by Roy Freeman, Christopher Gibbons, and Todd Dylan Levine. CND Life Sciences has raised $37.51 million across 13 funding rounds from investors including LabCorp, NIH and HHS. CND Life Sciences offers products and services including Syn-One Test and Small-Fiber DX. CND Life Sciences operates in a competitive market with competitors including BioShai, iNeuroskill, Itr Diagnostics and Parkinsor, among others.
- Headquarter Phoenix, United States
- Founders Roy Freeman, Christopher Gibbons, Todd Dylan Levine
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37.51 M (USD)
in 13 rounds
-
Latest Funding Round
Not available
-
Investors
LabCorp
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CND Life Sciences
CND Life Sciences offers a comprehensive portfolio of products and services, including Syn-One Test and Small-Fiber DX.
Skin-based test for diagnosing Parkinson's and related synucleinopathies.
Test for detecting small-fiber neuropathy in patients.
People of CND Life Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of CND Life Sciences
CND Life Sciences has successfully raised a total of $37.51M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CND Life Sciences
CND Life Sciences has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include LabCorp, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage companies are supported with growth capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for CND Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CND Life Sciences
Investment portfolio details for CND Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CND Life Sciences
Detailed financials for CND Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cnd Life Sciences Comparisons
Peer comparison for CND Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CND Life Sciences
CND Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioShai, iNeuroskill, Itr Diagnostics and Parkinsor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Offers blood-based tests for early diagnosis of Parkinson's disease.
|
|
| Locked | Locked | Locked |
A device that monitors the progression of neurological disorders by measuring motor skill characteristics.
|
|
| Locked | Locked | Locked |
Provides diagnostic tests for neurological diseases.
|
|
| Locked | Locked | Locked |
Develops diagnostic tools for diagnosing and treating Parkinson's disease.
|
Detailed competitors of CND Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cnd Life Sciences
Complete news archive for CND Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CND Life Sciences
CND Life Sciences was founded in 2017 and raised its 1st funding round 3 years after it was founded.
CND Life Sciences is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
Richard J Morello is the current CEO of CND Life Sciences.
CND Life Sciences is a funded company, having raised a total of $37.51M across 13 funding rounds to date.
Provider of a neurological disease diagnostic tool for providers. The company has developed a diagnostic kit called Syn-One Test which assists in the diagnosis of synucleinopathy in patients. The kit is a skin biopsy tool that has the ability to detect and visualize abnormal skin cell conditions based on pathological evidence.
CND Life Sciences's top competitors include BioShai, iNeuroskill and Itr Diagnostics.
CND Life Sciences offers Syn-One Test and Small-Fiber DX.
CND Life Sciences has 12 investors. Key investors include LabCorp, NIH, HHS, Tanis Ventures, and Top Corner Capital.